CoChat
Sign Up
Cited by 7Osteoarthritis Treatment and MechanismsBone and Joint DiseasesBone health and osteoporosis research

Association of biochemical markers with bone marrow lesion changes on imaging—data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium

Open access
Yu, Shirley P., Deveza, Leticia A., Kraus, Virginia B., Karsdal, Morten, Bay-Jensen, Anne-Christine, Collins, Jamie E., Guermazi, Ali, Roemer, Frank W. +3 more·2024·Arthritis Research & Therapy
DOI 10.1186/s13075-023-03253-xPMC PMC10795356
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: To assess the prognostic value of short-term change in biochemical markers as it relates to bone marrow lesions (BMLs) on MRI in knee osteoarthritis (OA) over 24 months and, furthermore, to assess the relationship between biochemical markers involved with tissue turnover and inflammation and BMLs on MRI. Methods: Data from the Foundation for the National Institutes of Health OA Biomarkers Consortium within the Osteoarthritis Initiative (n = 600) was analyzed. BMLs were measured according to the MRI Osteoarthritis Knee Score (MOAKS) system (0–3), in 15 knee subregions. Serum and urinary biochemical markers assessed were as follows: serum C-terminal crosslinked telopeptide of type I collagen (CTX-I), serum crosslinked N-telopeptide of type I collagen (NTX-I), urinary CTX-Iα and CTX-Iβ, urinary NTX-I, urinary C-terminal cross-linked telopeptide of type II collagen (CTX-II), serum matrix metalloproteinase (MMP)-degraded type I, II, and III collagen (C1M, C2M, C3M), serum high sensitivity propeptide of type IIb collagen (hsPRO-C2), and matrix metalloproteinase-generated neoepitope of C-reactive protein (CRPM). The association between change in biochemical markers over 12 months and BMLs over 24 months was examined using regression models adjusted for covariates. The relationship between C1M, C2M, C3M, hsPRO-C2, and CRPM and BMLs at baseline and over 24 months was examined. Results: Increases in serum CTX-I and urinary CTX-Iβ over 12 months were associated with increased odds of changes in the number of subregions affected by any BML at 24 months. Increase in hsPRO-C2 was associated with decreased odds of worsening in the number of subregions affected by any BML over 24 months. C1M and C3M were associated with BMLs affected at baseline. Conclusions: Short-term changes in serum CTX-I, hsPRO-C2, and urinary CTX-Iβ hold the potential to be prognostic of BML progression on MRI. The association of C1M and C3M with baseline BMLs on MRI warrants further investigation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13075-023-03253-x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rapid biomarker assays targeting inflammatory markers such as IL-1β, TNF-α, and IL-6 and indicators of cartilage degradation are being developed.

    “Targeting inflammatory markers like IL-1β, TNF-α, and IL-6 as well as indicators of cartilage degradation, rapid biomarker assays—such as lateral flow tests using antibody-coated nanoparticles (yielding results in 10–20 min with nanogram-range sensitivity), microfluidic lab-on-a-chip platforms (employing colorimetric, fluorescent, or electrochemical readouts), and multiplexed biosensors with”

    From Biomarker-Guided Imaging and AI-Augmented Diagnosis of Degenerative Joint Disease (2025) · cites this paper as [136]

    The Discussion (page unavailable) describes biomarkers of tissue inflammation and cartilage turnover, including C1M, C3M and C2M. It does not describe rapid assays being developed to detect IL-1β, TNF-α or IL-6, or the lateral-flow, microfluidic or multiplexed technologies in the citing sentence. Searches for those assay terms and cytokines found no supporting passage. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 58

  1. [1]Funck-Brentano T Cohen-Solal M Subchondral bone and osteoarthritis Curr Opin Rheumatol 2015 27 4 420 426 10.1097/bor.0000000000000181 26002035 · DOI
  2. [2]Walsh DA Sofat N Guermazi A Osteoarthritis bone marrow lesions Osteoarthritis Cartilage 2023 31 1 11 17 10.1016/j.joca.2022.09.007 36191832 · DOI
  3. [3]Tanamas SK Wluka AE Pelletier JP Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study Rheumatology (Oxford) 2010 49 12 2413 2419 10.1093/rheumatology/keq286 20823092 · DOI
  4. [4]Roemer FW Guermazi A Javaid MK Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: the MOST study. A longitudinal multicentre study of knee osteoarthritis Ann Rheum Dis 2009 68 9 1461 5 10.1136/ard.2008.096834 18829615 PMC2905622 · DOI
  5. [5]Felson DT Chaisson CE Hill CL The association of bone marrow lesions with pain in knee osteoarthritis Ann Intern Med 2001 134 7 541 549 10.7326/0003-4819-134-7-200104030-00007 11281736 · DOI
  6. [6]Laslett LL Dore DA Quinn SJ Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial Ann Rheum Dis 2012 71 8 1322 1328 10.1136/annrheumdis-2011-200970 22355040 · DOI
  7. [7]Cai G Aitken D Laslett LL Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: a randomized clinical trial JAMA 2020 323 15 1456 1466 10.1001/jama.2020.2938 32315057 PMC7175085 · DOI
  8. [8]Pelletier JP Roubille C Raynauld JP Disease-modifying effect of strontium ranelate in a subset of patients from the phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss Ann Rheum Dis 2015 74 2 422 429 10.1136/annrheumdis-2013-203989 24297379 · DOI
  9. [9]Mobasheri A Batt M An update on the pathophysiology of osteoarthritis Ann Phys Rehabil Med 2016 59 5–6 333 339 10.1016/j.rehab.2016.07.004 27546496 · DOI
  10. [10]Mobasheri A van Spil WE Budd E Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes Curr Opin Rheumatol 2019 31 1 80 89 10.1097/BOR.0000000000000567 30461544 · DOI
  11. [11]van Spil WE Degroot J Lems WF Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria Osteoarthritis Cartilage 2010 18 5 605 12 10.1016/j.joca.2010.01.012 20175979 · DOI
  12. [12]Kraus VB Collins JE Hargrove D Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers consortium Ann Rheum Dis 2017 76 1 186 195 10.1136/annrheumdis-2016-209252 27296323 PMC5851287 · DOI
  13. [13]Kraus VB Karsdal MA Clinical monitoring in osteoarthritis: biomarkers Osteoarthritis Cartilage 2022 30 9 1159 1173 10.1016/j.joca.2021.04.019 34536529 PMC8924021 · DOI
  14. [14]Hunter DJ Nevitt M Losina E Biomarkers for osteoarthritis: current position and steps towards further validation Best Pract Res Clin Rheumatol 2014 28 1 61 71 10.1016/j.berh.2014.01.007 24792945 PMC4010869 · DOI
  15. [15]Kraus VB Collins JE Charles HC Predictive validity of radiographic trabecular bone texture in knee osteoarthritis: the osteoarthritis research society international/foundation for the national institutes of health osteoarthritis biomarkers consortium Arthritis Rheumatol 2018 70 1 80 87 10.1002/art.40348 29024470 PMC5745253 · DOI
  16. [16]Collins JE Losina E Nevitt MC Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the foundation for the national institutes of health osteoarthritis biomarkers consortium Arthritis Rheumatol 2016 68 10 2422 2431 10.1002/art.39731 27111771 PMC5599158 · DOI
  17. [17]Hunter DJ Deveza LA Collins JE Multivariable modeling of biomarker data from the phase i foundation for the national institutes of health osteoarthritis biomarkers consortium Arthritis Care Res (Hoboken) 2022 74 7 1142 1153 10.1002/acr.24557 33421361 PMC8267050 · DOI
  18. [18]Roemer FW Kwoh CK Hannon MJ Semiquantitative assessment of focal cartilage damage at 3T MRI: a comparative study of dual echo at steady state (DESS) and intermediate-weighted (IW) fat suppressed fast spin echo sequences Eur J Radiol 2011 80 2 e126 e131 10.1016/j.ejrad.2010.07.025 20833493 · DOI
  19. [19]Thudium CS Lofvall H Karsdal MA Protein biomarkers associated with pain mechanisms in osteoarthritis J Proteomics 2019 190 55 66 10.1016/j.jprot.2018.04.030 29704569 · DOI
  20. [20]Bay-Jensen AC Platt A Siebuhr AS Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study Arthritis Res Ther 2016 18 13 10.1186/s13075-015-0913-x 26787505 PMC4719735 · DOI
  21. [21]Deveza LA Kraus VB Collins JE Association between biochemical markers of bone turnover and bone changes on imaging: data from the Osteoarthritis Initiative Arthritis Care Res (Hoboken) 2017 69 8 1179 1191 10.1002/acr.23121 27723280 PMC5385286 · DOI
  22. [22]Wirth W Hellio Le Graverand MP Wyman BT Regional analysis of femorotibial cartilage loss in a subsample from the Osteoarthritis Initiative progression subcohort Osteoarthritis Cartilage 2009 17 3 291 7 10.1016/j.joca.2008.07.008 18789729 PMC2778007 · DOI
  23. [23]Hunter DJ Guermazi A Lo GH Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis Knee Score) Osteoarthritis Cartilage 2011 19 8 990 1002 10.1016/j.joca.2011.05.004 21645627 PMC4058435 · DOI
  24. [24]Karsdal MA Byrjalsen I Bay-Jensen AC Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis–the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation BMC Musculoskelet Disord 2010 11 125 10.1186/1471-2474-11-125 20565725 PMC2902412 · DOI
  25. [25]Kraus VB Hargrove DE Hunter DJ Establishment of reference intervals for osteoarthritis-related soluble biomarkers: the FNIH/OARSI OA Biomarkers Consortium Ann Rheum Dis 2017 76 1 179 185 10.1136/annrheumdis-2016-209253 27343253 · DOI
  26. [26]Van Spil WE Nair SC Kinds MB Systemic biochemical markers of joint metabolism and inflammation in relation to radiographic parameters and pain of the knee: data from CHECK, a cohort of early-osteoarthritis subjects Osteoarthritis Cartilage 2015 23 1 48 56 10.1016/j.joca.2014.09.003 25205017 · DOI
  27. [27]Fan T Ruan G Antony B The interactions between MRI-detected osteophytes and bone marrow lesions or effusion-synovitis on knee symptom progression: an exploratory study Osteoarthritis Cartilage 2021 29 9 1296 1305 10.1016/j.joca.2021.06.008 34216729 · DOI
  28. [28]Zhu Z Ding C Jin X Patellofemoral bone marrow lesions: natural history and associations with pain and structure Arthritis Care Res (Hoboken) 2016 68 11 1647 1654 10.1002/acr.22871 26946066 · DOI
  29. [29]Arnold N Rehm M Buchele G Growth differentiation factor-15 as a potent predictor of long-term mortality among subjects with osteoarthritis J Clin Med 2020 9 10 3107 10.3390/jcm9103107 32993054 PMC7650798 · DOI
  30. [30]Bihlet AR Bjerre-Bastos JJ Andersen JR Clinical and biochemical factors associated with risk of total joint replacement and radiographic progression in osteoarthritis: data from two phase III clinical trials Semin Arthritis Rheum 2020 50 6 1374 1381 10.1016/j.semarthrit.2020.03.002 32249039 · DOI
  31. [31]Garnero P Peterfy C Zaim S Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study Arthritis Rheum 2005 52 9 2822 2829 10.1002/art.21366 16145678 · DOI
  32. [32]Sofat N Ejindu V Heron C biomarkers in painful symptomatic knee OA demonstrate that MRI assessed joint damage and type II collagen degradation products are linked to disease progression Front Neurosci 2019 13 1016 10.3389/fnins.2019.01016 31680799 PMC6803383 · DOI
  33. [33]Kuttapitiya A Assi L Laing K Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation Ann Rheum Dis 2017 76 10 1764 1773 10.1136/annrheumdis-2017-211396 28705915 PMC5629942 · DOI
  34. [34]Wang B Pramono HK Cicuttini FM Association between urinary C-telopeptide fragments of type II collagen and knee structure in middle-aged women without clinical knee disease Osteoarthritis Cartilage 2014 22 8 1136 1141 10.1016/j.joca.2014.06.008 24971869 · DOI
  35. [35]Luo Y Samuels J Krasnokutsky S A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis J Orthop Traumatol 2021 22 1 10 10.1186/s10195-021-00572-0 33687578 PMC7943687 · DOI
  36. [36]Luo Y He Y Reker D A novel high sensitivity type II collagen blood-based biomarker, PRO-C2, for assessment of cartilage formation Int J Mol Sci 2018 19 11 3485 10.3390/ijms19113485 30404167 PMC6275061 · DOI
  37. [37]Gudmann NS Wang J Hoielt S Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes Int J Mol Sci 2014 15 10 18789 18803 10.3390/ijms151018789 25329619 PMC4227247 · DOI
  38. [38]Bay-Jensen AC Manginelli AA Karsdal M Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study Osteoarthritis Cartilage 2022 30 1 92 99 10.1016/j.joca.2021.10.008 34737064 · DOI
  39. [39]Driban JB Lo GH Lee JY Quantitative bone marrow lesion size in osteoarthritic knees correlates with cartilage damage and predicts longitudinal cartilage loss BMC Musculoskelet Disord 2011 12 217 10.1186/1471-2474-12-217 21961433 PMC3190349 · DOI
  40. [40]Felson DT The current and future status of biomarkers in osteoarthritis J Rheumatol 2014 41 5 834 836 10.3899/jrheum.140094 24788463 PMC4438757 · DOI
  41. [41]Lotz M Martel-Pelletier J Christiansen C Value of biomarkers in osteoarthritis: current status and perspectives Ann Rheum Dis 2013 72 11 1756 1763 10.1136/annrheumdis-2013-203726 23897772 PMC3812859 · DOI · Paper page
  42. [43]Leeming D He Y Veidal S A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M) Biomarkers 2011 16 7 616 628 10.3109/1354750x.2011.620628 21988680 · DOI
  43. [44]Kjelgaard-Petersen CF Platt A Braddock M Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis Arthritis Rheumatol 2018 70 9 1419 1428 10.1002/art.40527 29669391 PMC6174937 · DOI
  44. [45]Bay-Jensen AC Platt A Jenkins MA Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis BMC Rheumatol 2019 3 3 10.1186/s41927-019-0052-0 30886991 PMC6390574 · DOI
  45. [46]Radojcic MR Thudium CS Henriksen K Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients Pain 2017 158 7 1254 1263 10.1097/j.pain.0000000000000908 28333699 · DOI
  46. [47]Wang SX Abramson SB Attur M Safety, tolerability, and pharmacodynamics of an anti-interleukin-1alpha/beta dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study Osteoarthritis Cartilage 2017 25 12 1952 1961 10.1016/j.joca.2017.09.007 28964890 · DOI
  47. [48]Loeser RF Beavers DP Bay-Jensen AC Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis: the Intensive Diet and Exercise for Arthritis trial (IDEA) Osteoarthritis Cartilage 2017 25 11 1822 1828 10.1016/j.joca.2017.07.015 28756278 PMC5650925 · DOI
  48. [49]van de Stadt LA Kroon FPB Thudium CF Serum biomarkers in prednisolone-treated hand osteoarthritis patients Rheumatology (Oxford) 2023 62 3 1350 1355 10.1093/rheumatology/keac442 35946535 PMC9977113 · DOI
  49. [50]Saberi Hosnijeh F Siebuhr AS Uitterlinden AG Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort Arthritis Res Ther 2016 18 81 10.1186/s13075-016-0976-3 27039382 PMC4818486 · DOI
  50. [51]Bay-Jensen AC Platt A Byrjalsen I Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study Semin Arthritis Rheum 2014 43 4 470 478 10.1016/j.semarthrit.2013.07.008 23932312 · DOI
  51. [52]Siebuhr AS Petersen KK Arendt-Nielsen L Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover Osteoarthritis Cartilage 2014 22 1 44 50 10.1016/j.joca.2013.10.020 24216059 · DOI
  52. [53]Bay-Jensen AC Byrjalsen I Musa K AB0839 identification of a inflammatory phenotype with higher likelihood of progression in OA: analysis of Womac Pain Sub-Questions, C3M and U-CTX-II from two phase 3 randomized clinical trials with treatment of symptomatic knee osteoarthritis Ann Rheum Dis 2015 74 Suppl 2 1180 1181 10.1136/annrheumdis-2015-eular.6095 · DOI
  53. [54]Alexander LC Jr McHorse G Huebner JL A matrix metalloproteinase-generated neoepitope of CRP can identify knee and multi-joint inflammation in osteoarthritis Arthritis Res Ther 2021 23 1 226 10.1186/s13075-021-02610-y 34465395 PMC8407005 · DOI
  54. [55]Arendt-Nielsen L Eskehave TN Egsgaard LL Association between experimental pain biomarkers and serologic markers in patients with different degrees of painful knee osteoarthritis Arthritis Rheumatol 2014 66 12 3317 3326 10.1002/art.38856 25168637 · DOI
  55. [56]Dudli S Ballatori A Bay-Jensen AC Serum biomarkers for connective tissue and basement membrane remodeling are associated with vertebral endplate bone marrow lesions as seen on MRI (Modic changes) Int J Mol Sci 2020 21 11 3791 10.3390/ijms21113791 32471173 PMC7312719 · DOI
  56. [57]Bay-Jensen AC Karsdal MA Ladel C C1M, C2M, C3M, PRO-C2, and CRPM in serum reflect different potential pathogenetic domains of osteoarthritis, data from check Osteoarthritis Cartilage 2018 26 S179 S180 10.1016/j.joca.2018.02.387 · DOI
  57. [58]Bay-Jensen AC Bihlet A Byrjalsen I Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis Sci Rep 2021 11 1 6583 10.1038/s41598-021-86064-x 33753821 PMC7985384 · DOI
  58. [59]Kraus VB Kepler TB Stabler T First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis PLoS ONE 2010 5 3 e9739 10.1371/journal.pone.0009739 20305824 PMC2840035 · DOI

Cited by

Sorted by citations

Authors
Yu, S. P., Deveza, L. A., Kraus, V. B., Karsdal, M., Bay-Jensen, A.-C., Collins, J. E., Guermazi, A., Roemer, F. W., Ladel, C., Bhagavath, V., & Hunter, D. J.
Affiliations
  • The University of Sydney (AU)
  • Duke University (US)
  • Nordic Bioscience (Denmark) (DK)
  • Brigham and Women's Hospital (US)
  • Boston University (US)
  • Hessisches Landesmuseum Darmstadt (DE)
Corresponding author
Yu, Shirley P.
ORCID
Venue
Arthritis Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2024-01-18
Volume
26
Issue
1
Pages
30-30
ISSN
  • 1478-6354 (ISSN-L)
  • 1478-6362
DOI
10.1186/s13075-023-03253-x
PMC
PMC10795356
OpenAlex
W4390977356
Cited by
7
References
1
Citations by year
2026: 2 · 2025: 4 · 2024: 1
FWCI
2.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Arthritis Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • University of Sydney (Postgraduate Scholarship (Merck PhD Scholarship in Medicine))
  • Foundation for the National Institutes of Health
  • National Institutes of Health (NIAMS K01AR075879)
  • Else Kröner-Fresenius-Stiftung
  • Nordic Bioscience
  • National Health and Medical Research Council (Investigator Fellowship)
Topics
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone and Joint Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
knee osteoarthritis, bone marrow lesions, biochemical markers, prognostic factors, collagen turnover, C-terminal telopeptide of type I collagen, matrix metalloproteinases, MOAKS, disease progression
MeSH terms
Bone Diseases, Bone Marrow, C-Reactive Protein, Collagen, Humans, Magnetic Resonance Imaging, Biomarkers, Osteoarthritis, Knee, Matrix Metalloproteinases, Collagen Type I

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review